Valsartan

ATC Code C09CA03

Valsartan

Definition

An orally active nonpeptide triazole-derived antagonist of angiotensin (AT) II with antihypertensive properties. Valsartan selectively and competitively blocks the binding of angiotensin II to the AT1 subtype receptor in vascular smooth muscle and the adrenal gland, preventing AT II-mediated vasoconstriction, aldosterone synthesis and secretion, and renal reabsorption of sodium, and resulting in vasodilation, increased excretion of sodium and water, a reduction in plasma volume, and a reduction in blood pressure.

Also known as CGP 48933, Diovan, L-Valine, N-(1-oxopentyl)-N-((2'-(1H-tetrazol-5-yl)(1,1'-biphenyl)-4-yl)methyl)-, N-(p-(o-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, VALSARTAN — per NCIT

Also identified as

Indications

Disease Relation Source
Diabetic kidney disease may treat MEDRT · Public domain (U.S. Government work)
Heart failure may treat MEDRT · Public domain (U.S. Government work)
Hypertensive disorder may treat MEDRT · Public domain (U.S. Government work)

Organ Effects

Organ Side effect / interaction Source
Adult mammalian kidney may treat a disease of this organ DERIVED · CC BY 4.0
Cardiovascular system may treat a disease of this organ DERIVED · CC BY 4.0
Genitourinary system may treat a disease of this organ DERIVED · CC BY 4.0
Heart may treat a disease of this organ DERIVED · CC BY 4.0
Renal system may treat a disease of this organ DERIVED · CC BY 4.0

5 entries above are marked DERIVED: Atlas Médico inferred them by combining two sourced claims, and no source asserts these links directly. Treat them as a navigation aid, not as a clinical statement.